Now through December 1st, 2014, Freudenberg will be hosting a contest in the area of smart surface technology for medical devices (preferably silicone based). Share your new product or business idea for the opportunity to launch a successful and innovative startup business in cooperation with Freudenberg.
About 15 years ago, the Cystic Fibrosis Foundation made what was considered a risky foray for a nonprofit organization into the world of business. It began giving money to a small biotechnology company to entice it to develop drugs for the deadly lung disease.
Ten years ago, scientists discovered that some people are naturally missing working copies of a gene known as PCSK9. The consequences of the mutation were extraordinary. These people, including a Texas fitness instructor, a woman from Zimbabwe, and a 49-year-old Frenchman, had almost no bad cholesterol in their blood. Otherwise, they were perfectly normal.
Wednesday, December 10, 2014 from 6:00 PM to 8:00 PM (EST), Rockville, Maryland
Climbing the Regulatory Summit: Insights into developing the Best Regulatory Pathway for your Venture and Methods of Designing an Efficient and Productive Clinical Trial
An absolutely essential exercise in any healthcare or life science start-up is to determine the optimal regulatory pathway and the most efficient clinical trial design. Come and hear the experts before you go spending those scarce resources!
In the “Mystery of Capital,” Peruvian economist Hernando de Soto famously writes about the need to convert assets into capital for creation of social and economic value in developing countries and economies in transition, noting: “Any asset whose economic and social aspects are not fixed in a formal property system is extremely hard to move in the market.” While de Soto is describing the need to legalize informal property systems, this is equally true with respect to BRICS and other countries seeking to unlock capital resources for R&D intensive start-ups, also known as Micro, Small and Medium Enterprises (MSMEs).
Are you an established public company looking to impress investors with your company’s latest developments, or a late-stage private company hoping to make the valuable connections needed to take your product to the next phase? Nominate your company to be the Buzz of BIO at the 2015 CEO & Investor Conference!
Ten biotechs will be nominated in each of two categories, “Most Distinguished Public Company” and “Most Promising Private Company.” Only 20 nominations will be accepted in total, and must be submitted by 5:00pm ET, November 21, 2014. All nominations are subject to review.
The US healthcare industry is undergoing a major transformation as healthcare reform encourages consumers to play a far more active decision-making role. Yet despite this traditionally business-to-business industry moving quickly to a business-to-consumer model, companies have been slow to join the digital movement. Unlike successful B2C companies in other industries—which offer mobile solutions, provide personalized product recommendations, and empower customer-service agents with a 360-degree view of the customer—most healthcare providers and payors are lagging, as are pharmaceutical companies and medical-device manufacturers.
The angel investor market in Q1,2 2014 showed signs that the five year moderate growth has continued in the first half of 2014. Total investments in Q1,2 2014 were $10.1 billion, an increase of 4.1% over Q1,2 2013, according to the Center for Venture Research at the University of New Hampshire. A total of 30,270 entrepreneurial ventures received angel funding in Q1,2 2014, a 5.9% increase from Q1,2 2013, and the number of active investors in Q1,2 2014 was 143,140 individuals, an increase of 6.1% from Q1,2 2013. The increase in total dollars and the larger increase in total investments (deals) resulted in a deal size of $332,120 in Q1,2 2014, a decline from the deal size in Q1,2 2013 of $337,850. These data indicate that angels remain major players in this investment class and at valuations similar to Q1,2 2013. The market exhibited a sustained growth pattern over a five year period and the angel market has now recovered from the correction in 2008.
More than half of all healthcare practitioners, or 57 percent, said that on “most days” they feel more attached to computers than their patients, according to a recent survey conducted at the Integrative Health and Medicine conference.
Big pharma companies are making greater efforts to improve access to medicines in the developing world, but corruption and intellectual property (IP) issues are areas of concern, says a new report.
The biannual Access To Medicines Index (ATMI) – which is funded by the Bill & Melinda Gates Foundation and the UK and Dutch governments – puts GlaxoSmithKline at the top of its rankings in 2014 for the fourth time, followed by Novo Nordisk and Johnson & Johnson.
